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Abstract 
Wheat bran cereals are an important source of dietary fibre. The aim of the study was to 
investigate if a high intake (120 g) of fibre rich breakfast cereal (which delivers the UK 
Government guidelines for fibre intake in one serving but is three-fold higher than the 
manufacturers recommended serving) has additional potential health benefits compared to 
the recommended serving (40 g, containing 11 g of dietary fibre). To assess this, the study 
determined the short chain fatty acid (SCFA) profiles in human faecal, urine and plasma 
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samples after consumption of two different servings of fibre-rich cereal. Inhibition of 
prostanoid production was measured (ex vivo) in human colonic fibroblast cells after cytokine 
(IL-1β) inflammation stimulation. Eight healthy volunteers, 18-55 years old; BMI (18-30 kg/m2) 
consumed the wheat bran-rich “ready to eat cereal”, at both the high (120 g) serving and 
recommended (40 g) serving. Faecal, urine and plasma samples were collected at baseline, 
throughout the five-hour intervention period and approximately 24 hours following 
consumption. Faecal butyrate showed the largest increase (p<0.05) of more than a two-fold 
change following the consumption of the recommended serving of wheat bran cereal (from 
13.95 ± 9.17 to 31.63 ± 20.53 mM) and no significant change following the higher serving 
(from 21.96 ± 11.03 to 22.9 ± 12.69 mM). ANOVA analysis also found a weak serving effect (p 
= 0.046) of the portion size (high vs. recommended) only for butyrate in urine 24 hours after 
consumption of the bran cereal. The physiological nutritionally relevant concentrations of 
faecal SCFAs, as determined in the volunteers’ faecal samples showed significant anti-
inflammatory activity or the individual faecal SCFAs; acetate (p<0.001), propionate (p<0.001) 
and butyrate (p<0.01), as well as in combination. Plasma folate was also increased after 
consumption of both wheat bran servings and was significant (p = 0.037) at the three-hour 
time point following consumption of the high wheat bran serving. The consumption of the 
recommended serving (40 g) of wheat bran cereal increased the total microbial SCFAs levels 
(from 96.88 to 136.96 mM) compared to the higher serving (120 g) (from 110.5 to 117.64 mM) 
suggesting that the intake of the higher portion size is likely to promote a faecal bulking effect 
and thereby decrease colonic SCFA levels. These data indicate that consumption of the 
recommended serving of wheat bran cereal serving would therefore be sufficient to promote 
microbial butyrate formation, reduce colonic inflammation and increase plasma folate levels 
in humans.  
Keywords  
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1. Introduction 
In 2015, as part of the initiative to promote a healthy balanced diet, the UK government changed 
the guidelines on the daily recommended dietary fibre intake to 30 g per day [1], representing 23 g 
of non-starch polysaccharides (NSP), a 5 g increase over the previous 18 g NSP recommendation [2]. 
This dietary fibre value (30 g/day) refers to AOAC fibre, meaning measured by the Association of 
Official Analytical Chemists' (AOAC) method [2]. However, most adults in the UK are only eating an 
average of approx. 18 g dietary fibre per day [1]. The UK data for adults [3] shows that cereal 
products contribute 37% of fibre intake and 28 % of total calorie intake and that wheat consumption 
is more than ten-times that of rice, oats, or maize [4]. Bran fractions produced by milling are 
nutritionally rich in minerals, vitamin B6, thiamine, folate and vitamin E, as well as phenolic 
compounds [5]. One of the richest sources of fibre from wheat bran-based products is breakfast 
cereals [4]. Furthermore, breakfast cereals are also an important source of folate in the human diet. 
Folate has a key role in ensuring normal development, growth, and maintenance of optimal health 
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[6] and maintaining an optimal folate status in the population is a public health priority, in 2021, the 
UK Government adopted mandatory folic acid fortification, and folate will be added to non-
wholemeal wheat flour across the UK to help prevent life-threatening spinal conditions in babies [7]. 
Metabolic changes associated with impaired folate status have been linked to increased risk of 
chronic diseases including cancer, cardiovascular disease and cognitive dysfunction [8].  The role of 
folic acid in gut heath is still a subject of debate [9]. 
Amongst other suggested mechanisms by which wheat bran could benefit gut health [10] is the 
production of microbially-produced short chain fatty acids (SCFA) mainly produced by the dense 
population of bacteria in the large intestine that ferment complex carbohydrates that escape 
digestion by host enzymes [11]. Much of the fermentation of these carbohydrates occurs in the 
proximal colon, with reduced levels of carbohydrates available for fermentation by bacteria in the 
distal colon which is the main site of polyp development [12]. These SCFA and in particular butyrate 
[13] are the major energy source for colonocytes and may modulate carcinogenesis through their 
effects on proliferation, differentiation and apoptosis in the gut, as well as stimulation of the 
immune system [14]. Many of the inflammatory pathways regulating the production of prostanoids 
are implicated in the development of colon cancer. Consequently, chemo-preventive strategies to 
inhibit development and induce regression of colorectal adenomas often involve modulation of the 
pathways regulating prostaglandin production [15].  
Meeting the dietary fibre daily recommendation is on the agenda of many countries, as globally 
only a few countries meet or exceed this amount. Little is known regarding the best consumption 
pattern to follow to achieve optimal health benefits from fibre consumption. The aim of this study 
was to investigate the potential health benefits of a three-fold higher intake of recommended (by 
manufacturer) serving size of wheat bran cereal (120 g), representing the approximate UK 
Government guidelines daily recommendation for fibre (33 g), compared with the manufacturer 
recommended serving (40 g) consumption in one meal, representing approximate a third of the 
daily fibre recommendation (11 g). The study measured the concentrations of SCFAs faecal, urine 
and plasma samples and plasma folate following the consumption of two different servings of wheat 
bran cereals by healthy human volunteers. The study also determined the impact of physiologically 
relevant in vivo faecal SCFA concentrations, mixtures and ratios measured in healthy volunteers 
following the consumption of wheat bran cereals on inhibition of prostanoid production using 
colonic fibroblast cells (ex vivo). The outcome of this study suggests that a recommended 40 g 
serving of bran cereal results in increased levels of faecal butyrate which is likely to be health 
protective. 
2. Materials and Methods 
2.1 Human Study  
2.1.1 Study Design 
Details of the human dietary intervention study were published previously [16]. Briefly, eight 
healthy volunteers (seven females, one male), 38.62 ± 10.8 years old; 23.39 ± 2.63 kg/m2 (BMI), 
were recruited for a non-randomised, cross-over acute human dietary intervention study. Written 
informed consent was obtained from each subject. Each volunteer consumed wheat bran-rich 
cereals, a high (120 g) serving with semi-skimmed milk (375 mL)- HWB (high wheat bran and a 40 g 
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serving with semi-skimmed milk (125 mL)- WB (manufacturer recommended portion of wheat bran), 
following a three-day low phytochemical and fibre diet. No food and drinks (apart from water) were 
consumed by the volunteers until the completion of collection of 5 h blood and urine samples. There 
was a washout period of at least two weeks between interventions. Volunteers were fasted for 12 
h prior to commencing the intervention and were requested not to drink or eat anything within the 
first 5 h following consumption. For the remaining intervention period (24 h), volunteers could 
consume the low phytochemical diet. Faecal, urine and blood samples were collected prior to the 
beginning of each intervention and at 1, 3, 5 and 24 hours (for bloods and urine) and first faecal 
sample after consuming the cereals, labelled as 24 h for simplicity (Figure 1). 
 
Figure 1 Human dietary intervention study diagram: Each volunteer (n = 8) consumed 
wheat bran-rich cereals at three times the manufacturer’s recommended serving (120 
g) with semi-skimmed milk (375 mL) – HWB (High Wheat Bran intervention day) and one 
recommended serving (40 g) along with semi-skimmed milk (125 mL)-WB (Wheat Bran 
Intervention day) following a 3-day low phytochemical and fibre diet with a washout 
period of at least two weeks between intervention days. Sample collection: prior test 
meal, baseline (0 h) and first faecal sample after wheat bran consumption (approx. 24 h 
after); baseline (0 h), 1, 3, 5 and 24 h blood; and baseline (0 h), 1, 3, 5, overnight (from 
5 h until 24 h) and 24 h urine. 
2.1.2 Intervention Product 
The study used All Bran original cereal (Kellogg’s, UK). According to the manufacturer, one 
recommended serving (40 g) of the product with 125 ml milk contain 10 g protein, 25 g carbohydrate 
(of which 13 g sugars, 12 g starch), 3.5 g fat (of which 1.5 g saturated fat), 11 g fibre and 0.8 g salt. 
According to the manufacturer one recommended serving of wheat bran cereals (40 g) contains 108 
µg folic acid, providing 54% of the folate RDA. 
2.1.3 Human Sample Processing 
The faecal, urine and blood samples were processed as previously described [16] and stored at –
80˚C until SCFA and plasma folate analysis was performed. Briefly, blood samples were collected 
directly into heparinised tubes at the 0, 1, 3, 5 and 24 h time points. The samples were centrifuged 
(1500 × g, 15 min; 4 °C) within 45 min to separate the plasma. Urine samples were measured by 
weight and volume at the same time points up to 5 h, and then the total 24-h sample collected. The 
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harvested plasma and the urine were aliquoted and stored at –80 °C. The faecal samples were 
weighed, mixed and immediately frozen at –80 °C. Faecal samples were thawed, mixed once again, 
weighed and the faecal waters separated using a high-speed centrifuge (50 000 × g; 2 h; 10 °C). The 
supernatant (faecal water) was carefully removed, aliquoted into Eppendorf tubes and immediately 
stored at –80 °C for analyses.  
2.2 Human Samples Analysis  
2.2.1 Analysis of SCFAs in Urine, Plasma and Faecal Samples 
Acetate, propionate and butyrate were analysed by GC-MS as previously described [17] following 
derivatisation of the samples using N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide 
(MTBSTFA). To an accurately weighed (0.4 g) plasma and urine sample 0.025 g of internal standard 
(13C isotopes of acetic, propionic, and butyric) and approximately 10 mg of 5-sulphosalicylic acid 
was added. The internal standards for acetic, propionic and butyric were added to plasma and urine 
samples and proceed the extraction and derivatisation for GC-MS analysis using MTBSTFA (30 %) in 
acetonitrile. For the analysis of acetic, propionic and butyric acids from the faecal samples, 10 µL of 
faecal water was added to 1.855 mL of water, then 200 µL was transferred and prepared for analysis 
as described above. The samples were analysed using an Agilent 5973 MSD GC-MS. Separation was 
achieved using an Alltech EC1 capillary column 30 m x 0.25 mm ID x 0.25 μm film thickness. Samples 
were injected (1 μL) in split mode 40:1. Helium was used as the carrier gas. The injector temperature 
was 250 ºC, the interface temperature 250 ºC, the source temperature 230 ºC, and the Quad 
temperature 200 ºC. Ions monitored (areas obtained) for labelled and unlabelled SCFA were as 
follows (M+1/M+ apart from butyric M+2/M+): acetic, 117.1 & 118.1; propionic, 131.1 & 132.1; and 
butyric 145.2 & 147.2. 
2.2.2 Analysis of Plasma Folates 
Plasma folate was measured using a radioactive competitive binding assay SimulTRAC-SNB 
Radioassay Kit Vitamin B12 [57Co]/Folate [125I], ICN Diagnostics, Orangeburg, NY. 
2.3 Cell Culture 
Human colonic fibroblast cells CCD-18Co (CRL-1459) were obtained from the American Type 
Culture Collection Middlesex, England. Cells were purchased at a population doubling (PDL) of 27, 
and all studies were performed on cells from the fifth passage (PDL 30.7). The number of viable cells 
was measured using a colorimetric assay CellTiter96\AQueous; Promega; Madison, WI.  
2.4 Anti-inflammatory Screening Assay Cell Culture 
The ability of the SCFAs to inhibit neoplastic prostanoid production in colon cells following an 
inflammatory insult was performed as described previously [15]. The fibroblast cells (passage 5; PDL 
30.7) were seeded at a density 1x104 well-1. The cells were treated with acetate (73.57 mM), 
propionate (26.46 mM), and butyrate (27.27 mM) and their mixture respectively as mean 
concentrations, determined in the faecal water samples after the consumption of wheat bran 
servings, thirty minutes prior to stimulation with IL-1β. Prostaglandin concentrations were 
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measured using a prostaglandin screening EIA kit (Cayman Chemicals; Ann Arbor, MI) designed to 
measure a wide range of prostanoids. 
2.5 Statistical Analysis  
All data are expressed as mean ± standard deviation (STD). The effect of treatment on SCFA was 
assessed by analysis of variance, with each time point considered a distinct outcome, with terms for 
volunteer, treatment and baseline value. There were some indications of skewed distributions, so 
analysis was repeated on a log scale to confirm conclusions. The cell culture data and folate levels 
were analysed by paired t-tests to examine the differences between treatments and concentrations 
of SCFA used. 
2.6 Ethics Statement  
The study followed all the principles of the Declaration of Helsinki and good clinical practice, and 
all procedures involving human subjects were reviewed and approved by the Rowett Institute Ethics 
Panel, Study Number 2001, University of Aberdeen, UK. The study was registered with 
clinicaltrial.gov, study ID number: NCT02177279. 
3. Results 
3.1 SCFA Content of Human Faecal Waters, Plasma, and Urine  
Faecal waters contained the highest concentrations of SCFA (Table 1) compared to that of plasma 
(Figure 2A) and urine samples (Figure 2B). The highest increase in faecal SCFA concentration when 
compared with baseline values was following consumption of WB serving for butyrate (more than 
two-fold increase) Table 1. The overall mean concentrations of SCFA in the faecal water samples 
following the consumption of both WB and HWB (for n = 8 volunteers) were 73.57 ± 30.77 mM for 
acetate; 26.46 ± 11.45 mM for propionate and 27.27 ± 17.09 mM for butyrate. Samples collected 
following the intervention showed no significant changes in faecal samples weights and total faecal 
waters produced between baseline and first sample produced following HWB consumption (p>0.05, 
t test) and WB consumption (p>0.05, t test) (Table S1, supplementary information). 
Table 1 SCFA faecal water concentrations (mean ± STD; n = 8) and % change between 
baseline and post intervention following wheat bran (WB) and high wheat bran (HWB) 
consumption. 
 HWB (120 g) WB (40 g) 










Acetate 65.59±16.9 69.19±24.26 +5.48 60.62±15.86 77.95±37.37 +28.58 
Propionate 22.68±10.03 25.55±10.08 +12.65 22.31±9.76 27.38±13.31 +22.75 
Butyrate 21.96±11.03 22.9±12.69 +4.28 13.95±9.17 31.63±20.53 +126.78* 
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Total (mM) 110.23 117.64 +6.72 96.88 136.96 +39.54 
% Butyrate 
 (from total) 19.91 19.46 -2.31 14.36 23.09 +62.19 
Significant changes in SCFAs measured in faecal waters refer to the difference between time 0 
(baseline) prior the consumption of the test meals and the post intervention sample after 
consumption of test meals, where * p<0.05, significant change between baseline and post 
intervention (t-test). 
 
Figure 2 Plasma distribution (A) and urine distribution (B) of SCFA concentration (mean 
± STD, for n = 8 volunteers) of acetate, propionate, butyrate and total SCFAs measured 
in human plasma samples at baseline (0 h), and 1, 3, 5, 24 h and baseline (0h), and 1, 3, 
5, (overnight from 5 h to 24 h, on plot 19 h), 24 h (for urine samples) after consumption 
of HWB, (black) and respectively recommended serving of WB (grey). Where * stands 
for p<0.05 and *** for p<0.001 for significant change vs baseline, when calculated with 
t-test. All the significance changes in SCFAs measured in biological samples refer to the 
difference between time 0 (baseline) prior the consumption of the test meals and time 
points after consumption of test meals. 
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There were significant effects overall with time for propionate (p<0.05), and with time (p = 0.01), 
and serving (p<0.05) for butyrate. This translates to a significant increase (p = 0.024, t-test) in 
butyrate concentration in faecal samples following WB consumption (from 13.95 ± 9.17 mM to 
31.63 ± 20.5 mM), representing a 127 % increase. The results presented in this in vivo study are in 
accordance with previous research [18], where in vitro butyrate levels were also elevated when bran 
was fermented by mixed microbiota in studies conducted in model colonic fermenter systems. 
In the plasma samples, acetate was the most concentrated SCFA found, with the highest levels 
determined at 5h after consumption of WB and HWB (115.51 ± 24.07 and 120.43 ± 27.84 µM 
respectively), followed by propionate and butyrate. ANOVA showed an overall significant effect 
(p<0.001) for time on plasma concentrations for acetate (at 1h p<0.001, and 5 h p<0.01; t-test). This 
translates to a significant decrease in plasma acetate concentration at 1 hour after HWB 
consumption (from 94.36 ± 12.68 µM to 68.32 ± 7.87 µM, n = 8; p<0.001, t-test) and at 1 hour after 
WB (from 90.19 ± 19.71 µM to 71.22 ± 7.67 µM; p<0.01, t-test); and a significant increase in plasma 
acetate at 5 hours after WB consumption (from 90.19 ± 19.71 µM to 115.51 ± 24.07 µM; p<0.05, t-
test). 
The SCFA distribution pattern in urine was similar to plasma; for butyrate at 24 h where there 
was a weak serving effect (p<0.05, ANOVA). Overall, ANOVA showed a significant effect (p<0.05) for 
time and butyrate concentration with t-test values of p<0.05 at 3 h; p<0.01 at 5 h; and p<0.05 
overnight. There was also a significant effect for time for acetate at 5 h and overnight (p<0.05) in 
comparison with baseline. These translates to a significant decrease (p<0.05, t-test) in butyrate 
concentration overnight for urine samples after WB consumption (from 0.33 ± 0.14 µM to 0.23 ± 
0.08 µM). 
There was a significant decrease of plasma total SCFAs concentration at 1 h (vs baseline) 
following WB (p<0.05, t-test) and HWB (p<0.001, t-test) and a significant increase in 5 hours plasma 
following both WB and HWB (p<0.05, t-test) (Figure 2 A). Total SCFAs concentration were 
significantly reduced (p<0.05, t-test) in overnight urine samples following HWB consumption (Figure 
2B). 
There were no differences between the wheat bran servings (HWB and WB) in plasma or urine 
concentrations of SCFAs. 
3.2 Folate Plasma Content 
Consumption of wheat bran led to an increase of plasma folate levels following both 
recommended and high servings WB (from 6.95 ± 0.62 to 8.17 ± 0.43 ng/mL, n = 8 in 5 h) and HWB 
(from 6.77 ± 0.62 to 9.00 ± 0.74 ng/mL, n = 8 in 3h). This rise was significant (p<0.05, t-test) only 
after consuming the HWB serving (Figure 3). 




Figure 3 Plasma folate (mean ± SEM, for n = 8 volunteers) for at baseline (0 h), and 1, 3, 
5 h after consumption of high wheat bran (HWB, black) and recommended serving of 
wheat bran (WB, grey). Where * stands for p<0.05 for significant change in time versus 
baseline (0 h), when calculated with t-test. 
3.3 Effect of SCFA on Cell Viability and Determination of Anti-inflammatory Activity 
The cells were found to be between 94 and 100 % viable without stimulation and between 90 
and 93 % viable when stimulated with IL-1β. When unstimulated the SCFA-treated fibroblast colon 
cells produced a significantly (p<0.01) lower amount of prostanoids than the untreated control 
(10.54 ± 1.74 ng) only in the presence of acetate (Figure 4). In the presence of an inflammation 
stimulator (IL-1β), all of the SCFA significantly reduced the amount of prostanoids produced. In the 
presence of acetate (24.69 ± 1.98 ng, p<0.001, t-test), propionate (26.46 ± 2.95 ng, p<0.01, t-test), 
butyrate (21.92 ± 3.73ng, p<0.001, t-test), and in presence of their mixture was the lowest 
concentration of the prostanoids produced (20.69 ± 1.03 ng, p<0.001, t-test). 




Figure 4 Prostanoid concentrations (mean ± STD, n = 6) in human colonic fibroblast cells 
(CCD-18Co) with (black) and without (grey) cytokine-induced stimulation with IL-1β in 
the presence of short chain fatty acids (SCFAs). SCFAs were tested at mean in vivo 
concentrations; 73.57 mM, 27.27 mM and 24.26 mM for acetate, butyrate and 
propionate respectively. The mixture was a combination of all three SCFAs at the 
relevant concentrations. The non-supplemented media was used as control. Where * 
stands for p<0.05, ** for p<0.01 and *** for p<0.001, for significant change(t-test). The 
significance refers to the difference in prostanoid concentration between media control 
and SCFAs presence in both cases with or without stimulation for inflammation. 
4. Discussion 
After the consumption of one recommended serving of wheat bran cereal (WB; 40 g), the 
increase in concentration of the three major SCFAs in faecal samples (compared with the baseline) 
was higher than after the consumption of three times the recommended serving of wheat bran 
cereal (HWB; 120 g) and in particular resulted in a 62.19% increase vs a 2.3% decrease in faecal 
butyrate levels as a proportion of the total SCFAs following intakes of the standard WB and HWB 
servings respectively. This suggests that increasing cereal fibre intakes above the recommended 
portion size does not translate into greater levels of faecal SCFAs. One possible explanation is that 
markedly increasing the portion size could impact on gut transit, with the high level of fibre 
increasing faecal bulking and gut transit and resulting in lower bacterial fermentation of dietary 
fibre and an increase in the presence of unfermented dietary fibre in stool samples [19, 20]. 
However, this is only a hypothetical explanation as unfermented dietary fibres in the stool were not 
measured in this study. This may therefore provide evidence for why the recommended portion size 
of bran may actually provide more benefits, with respect to faecal butyrate levels, than the high 
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serving. Therefore, increasing the amount of cereal consumed at one meal (i. e. consuming all the 
daily recommended dietary amount of 30 g) seems unlikely to provide additional benefits with 
respect to SCFA levels in faecal samples to promote gut health. In this case 40 g of wheat bran 
cereals, equivalent to 11 g of dietary fibre (one third of the daily recommended amount) in one 
meal would deliver potential benefits associated with SCFA production by allowing the fibre to be 
properly fermented and for the SCFAs (especially butyrate) to be produced and increased in the 
colon. Other studies have also reported on the impact of increasing dietary fibre intakes and found 
no significant increase in faecal SCFAs concentrations [21, 22]. The main difference between these 
studies and the present study is that in the present study the samples were collected following 
chronic consumption of a cereal fibre whilst in other studies the specific type of fibre (which was 
often mixed fibres present in fruits and vegetables, therefore likely to be rich in pectin) and source 
is not specified. 
There is a plethora of evidence of the benefits associated with consumption of high and 
recommended amounts of dietary fibre in diets, such as increase gut motility [23], body weight 
control [24], decreased chronic inflammation [25], and a reduction in cardiovascular disease [26], 
however details on the source and the quantity of fibre consumed is sometimes lacking. 
The folate levels were elevated, but only significantly different from baseline following the 
consumption of the HWB meal, and not after the WB serving; demonstrating that the folate in the 
bran cereals is likely to be bioavailable in a concentration dependant manner. This is important as 
achieving and maintaining a clinical normal range of folate in blood through diet is a public health 
priority due to the multiple implications and role of folate in human health. This also proves that 
the whole meal type foods such all-bran cereals are a valuable source of bioavailable folate to 
complement the mandatory UK fortification of foods [7].  
It is essential to identify the types of cells, immune responses, tissue inflammation, and diseases 
that are highly responsive to SCFA-based therapies or high dietary fibre consumption. Although up-
regulated PGHS-2 and increased prostanoid synthesis are implicated in the early stages of colorectal 
neoplasia, its expression is hardly detectable in normal and pre-malignant colorectal epithelium and 
is perhaps confined to sub-epithelial cells, such as fibroblasts [27]. The colonic fibroblasts are 
potentially important targets, as cytokine induction results in a significant increase of PGHS-2 and 
that fibroblasts and their products are crucial determinants of epithelial cell behaviour; research 
suggesting [28] that fibroblasts could be important cytokine targets in the colon. Therefore, the 
determination of anti-inflammatory activity using a previously validated fibroblast cell model [15] 
and is important this will give important information of the role of SCFAs in inflammatory processes. 
Research has also shown that circulating SCFA can have an effect on systemic macrophage and 
dendritic cell (DC) biology, illustrating the strong connection between dietary fibre intake and many 
types of immune responses under the control of DC or macrophages [29]. Consequently, is it 
important to determine the nutritionally relevant concentration of both SCFA at both the systemic 
and gut levels achieved after fibre-rich meal consumption by humans. 
It was observed that unstimulated fibroblast colon cells produced a significantly lower amount 
of prostanoids than the untreated control cells, only in the presence of acetate. This is important, 
since acetate was present at the highest levels in the faecal water samples and suggests a role in 
maintaining gut homeostasis. All SCFAs at the nutritionally relevant concentrations measured in 
volunteers’ faecal samples, significantly reduced the production of neoplastic prostanoids when the 
cells were stimulated with Il-1β, with the SCFA mixture having the strongest effect. This suggests 
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that SCFAs will play a role in protecting against upregulation of inflammation.  Another key and 
important finding of this paper is that butyric acid, which had the overall highest increase following 
consumption of wheat bran cereals gave the highest anti-inflammatory response. 
5. Study Limitations 
The present study has several limitations. A relatively small sample size of eight participants limits 
the conclusions that can be drawn from the study, highlighting the importance to replicate our 
findings in a larger sample size (especially on the trends observed for plasma folate distribution). 
Additionally, the sequence by which the two portion sizes of cereal were consumed in was not 
randomized, however the timing of the interventions was adequately spaced out (minimum two 
weeks between each) and therefore there should be no carry over between treatments. Faecal SCFA 
levels are a proxy for intestinal levels however because as much (around 95%) of the acids are likely 
to be rapidly absorbed by the colonocytes [30]. 
6. Conclusions 
This study suggests that consumption of a recommended serving of wheat bran breakfast cereal 
of 40 g, representing 11 g dietary fibre in one meal, is sufficient to support a butyrogenic 
fermentation with both butyrate levels and proportions increased compared to baseline samples. 
This is important for gut heath as butyrate is the main energy source for colonocytes [31, 32]. Wheat 
bran breakfast cereals are an important dietary source of fibre and the recommended 40 g serving 
could provide approximate 11 g of the daily recommendation for fibre. The study also suggests that 
meals with a higher fibre content, such as consuming all the daily recommended fibre intake in one 
meal may not necessarily be beneficial, as the promotion of faecal bulking is likely to increase gut 
transit and potentially decrease microbial fermentation.  
Nutritionally relevant concentrations of SCFAs are likely to significantly inhibit colonic 
inflammation by reducing the formation of prostanoids; moreover, a mixture of the measured SCFAs 
proved to be the most efficient. Furthermore, acetate-treated fibroblasts produced a significantly 
lower endogenous amount of prostanoids compared to the control suggesting a role in gut 
homeostasis. In addition, wheat bran-based foods (breakfast cereals) are likely to contribute to 
maintaining clinically normal ranges of plasma folates. 
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Table S1 Actual faecal sample weights (g) produced by the volunteers at baseline and 
post intervention following HWB and WB. 
  
HWB 
Faecal weight (g)   
WB 
Faecal weight (g)   
vol  Baseline Post Intervention Baseline Post Intervention 
vol 1 30.10 26.43   68.00 16.00   
vol 2 144.60 64.30   94.50 79.60   
vol 3 172.60 225.90   104.00 14.00   
vol 4 144.80 111.80   52.20 93.00   
vol 5 3.40 39.90   3.70 205.00   
vol 6 50.80 87.40   43.60 48.00   
vol 7 56.20 14.78   20.00 17.40   
vol 8 106.50 203.10   33.80 85.00   
 
